MedWatch

Lundbeck eyes progress in 2022, disappoints compared to consensus

On Wednesday morning, Lundbeck has publicized its full-year financial figures for 2021. Sales of core products grew by 15 percent, but the company is still handing in results slightly below expectations.

Photo: Jens Dresling

On Wednesday, pharmaceutical firm Lundbeck has released its full-year financial figures for 2021.

In connection with the report, Lundbeck has also showcased its 2022 outlook. The company hopes to end 2022 with a revenue of DKK 16.7–17.3bn (USD 2.56–2.65bn) and operating profits (EBIT) of DKK 2.2–2.6bn (USD 337.6–399m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs